Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUN-627 in non-active progressive multiple sclerosis
2026-525817-29-00Phase 2Authorised
- Sponsor
- Sundance Biosciences
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of SUN-627 in multiple sclerosis (MS), primary progressive multiple sclerosis (PPMS) and secondary-progressive multiple sclerosis (SPMS), sponsored by Sundance Biosciences. Planned start Oct 2026; status: authorised.
02
Drugs
SUN-627
03
Conditions
multiple sclerosis (MS)primary progressive multiple sclerosis (PPMS)secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on 2026-525817-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525817-29-00.